incretin glp 1 Targeting both receptors together for a new generation of diabetes therapies Incretin-based therapy of metabolic disease

First clinical trial to investigate the efficacy and safety of combined SGLT2 inhibitor and GLP-1R agonist therapy in patients with T2DM, suggesting additive or synergistic effects on weight loss

Most hair-focused copper peptide protocols use 1% to 3%, with concentrations above 3% increasing risk of scalp irritation and redness

This impairment can happen because the body releases less GLP-1, breaks it down too quickly, or does not respond to it effectively

While some patients choose to continue medications long-term at maintenance doses, others successfully maintain their weight loss through the healthy habits they've developed